Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Fuji Pharma 9-Mos Net Y1.82B Vs Net Y1.83B
Fuji Pharma Co. Ltd. (4554.TO) Japan Nine Months Ended June 30 GROUP 2026 2025 Revenue Y45.38 bln Y36.95 bln Operating Profit Y5.39 bln Y3.37 bln Pretax Profit Y5.48 bln Y3.16 bln Net Profit Y1.82 bln Y1.83 bln Per share Earnings Y72.11 Y75.07…
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale
Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and integration risk. The reports had the industry…
Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms
Generic drugmaker Aurobindo Pharma reported a 25.2% year-on-year (YoY) increase in consolidated net profit to ₹1,032 crore in the June quarter FY27. The higher net profitability came on a 16.3% YoY increase in revenue from operations to…
Gland Pharma, Neuland Laboratories team up for sterile API manufacturing
Gland Pharma and Neuland Laboratories have entered into a long-term a contract development and manufacturing organisation (CDMO) partnership under which Gland will establish a sterile manufacturing suite for active pharmaceutical ingredients (APIs)…
Royalty Pharma Q2 Earnings Call Highlights
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress…
HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, August 4th. HC Wainwright analyst J. Pantginis now forecasts…
Aurobindo Pharma Q1 profit rises 25% as revenue hits record ₹9,150 crore
Aurobindo Pharma's net profit increased 25 per cent at Rs ₹1,032 crore in the first quarter ended June 30, 2026, compared to ₹824 crore in the corresponding quarter of the previous year. The Hyderabad-based company recorded its…
Zealand Pharma A/S (ZLDPF) Projected to Post Earnings on Thursday
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) will likely be announcing its results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of $0.1431 per share and revenue of $128.9080 million for the…
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of 'Hold' by Analysts
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) has been given a consensus rating of 'Hold' by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a…
Royalty Pharma (NASDAQ:RPRX) Announces Earnings Results, Misses Expectations By $1.23 EPS
Royalty Pharma (NASDAQ:RPRX - Get Free Report) issued its earnings results on Wednesday. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($1.23), FiscalAI reports.
Bank of America Corp DE Buys 786,921 Shares of Royalty Pharma PLC $RPRX
Bank of America Corp DE grew its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 29.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,495,846 shares…
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - What's Next?
Urogen Pharma (NASDAQ:URGN - Get Free Report) hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as $47.84 and last traded at $46.43, with a volume of 2480596 shares. The stock had previously closed at $39.92. 3…
Urogen Pharma (NASDAQ:URGN) Given New $75.00 Price Target at HC Wainwright
Urogen Pharma (NASDAQ:URGN - Get Free Report) had its price objective raised by investment analysts at HC Wainwright from $45.00 to $75.00 in a report issued on Thursday, Marketbeat.com reports. The firm currently has a 'buy' rating on the stock.
Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1% - Here's Why
Urogen Pharma (NASDAQ:URGN - Get Free Report)'s share price was up 9.1% during mid-day trading on Wednesday. The company traded as high as $43.99 and last traded at $43.56. Approximately 193,743 shares were traded during mid-day trading, a decline…
Receive a Daily briefing on Pharma Industry News
Get Started